Small molecule · Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4) · developed by Pf Prism Cv
ApprovedFDA, Jan 2012
What is Axitinib?
Axitinib is a kinase inhibitor that blocks vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3, inhibiting VEGF-mediated endothelial cell proliferation and survival and tumor angiogenesis. It is studied in advanced malignancies, non-small cell lung cancer, ovarian cancer, urothelial cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Inlyta
Drug type
Small molecule
Targets
VEGFR-1 (FLT1), VEGFR-2 (KDR), VEGFR-3 (FLT4)
Mechanism
Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4)
Pathways
VEGF-mediated angiogenesis, endothelial cell proliferation and survival
From the indications section of the FDA label (version of Mar 12, 2026). Read the full label for the exact wording, limitations and safety information.
Conditions studied
Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.